Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Messerli
F H
FH
Department of Hypertension, Ochsner Medical Institutions, New Orleans, LA 70121, USA.
D016907:Adverse Drug Reaction Reporting Systems; D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002752:Chlorthalidone / Q000009:adverse effects / Q000627:therapeutic use; D017292:Doxazosin / Q000009:adverse effects* / Q000627:therapeutic use; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*; D014481:United States
D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D017292:Doxazosin; D002752:Chlorthalidone